: The UCLA APT CTU is a multidisciplinary, research group composed of a core administrative unit and four clinical research sites (CRS) in metropolitan Los Angeles and one CRS in Southern Brazil (Figure 1.1). We have over 20 years of leadership experience in the design, implementation, and conduct of clinical trials evaluating both therapeutic and prevention strategies in diverse populations across all age groups. Under the leadership of Judith Currier M.D., M.Sc. and an experienced multidisciplinary investigator team including Eric Daar, M.D., Margaret Keller, M.D., Karin Nielsen, M.D., Steve Shoptaw, Ph.D., Yvonne Bryson M.D., Ronald Mitsuyasu, M.D., Raphael Landovitz, M.D., Breno Santos, M.D., and Stephen Brown M.D., we will participate in the design and conduct of studies addressing the priority areas; Therapeutics for HIV/AIDS and HIV-Associated Infections in both Adults and Maternal/Pediatric Populations, Integrated Strategies to Prevent HIV Infection, and Vaccines to Prevent HIV Infection. The CTU has an administrative core and CRS at UCLA and additional CRSs at Harbor-UCLA Medical Center, UCLA Vine Street Clinic, AIDS Research Alliance (ARA) and in Porto Alegre, Brazil. The CTU provides a gateway for the contributions of a cadre of outstanding established and emerging investigators at UCLA to contribute to clinical trials in HIV/AIDS. The goal of the UCLA APT CTU is to enroll diverse populations (encompassing adult, maternal and pediatrics) of HIV-infected and at-risk individuals from urban Los Angeles and Southern Brazil into therapeutic and prevention trials.
The specific aims of our unit are to:
AIM 1 :To make significant contributions to the development, conduct and leadership of studies in adult, maternal and pediatric HIV therapeutics.
AIM 2 : To evaluate and optimize integrated strategies to prevent HIV infection in diverse populations AIM 3: To conduct Phase l-lll trials to evaluate novel vaccine strategies to prevent HIV in all age groups AIM 4: To mentor new investigators in cross-disciplinary HIV/AIDS research as it relates to improving treatment, care management and prevention in diverse populations, including substance users.
AIM 5 : To simulate and support community involvement in HIV/AIDS research by maintaining active CABs and by facilitating greater participation of women and racial/ethnic minorities in the clinical trils conducted at the UCLA APT CTU.

Public Health Relevance

Worldwide there are 33 million people estimated to be living with HIV infection. Progress in the development of effective antiretroviral therapy and both biomedical and behavioral interventions for the prevention of HIV/AIDS has been phenomenal in the past thirty years, yet many important challenges remain. The clinical trials unit proposed will conduct high impact studies to evaluate new approaches to treating HIV infection and related complications and to preventing new cases of HIV through biomedical and vaccine research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069424-12
Application #
9386080
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Greenfield, Teri L
Project Start
2007-02-01
Project End
2020-11-30
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
12
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Hermanstyne, Keith A; Green Jr, Harold D; Cook, Ryan et al. (2018) Social Network Support and Decreased Risk of Seroconversion in Black MSM: Results of the BROTHERS (HPTN 061) Study. J Acquir Immune Defic Syndr 78:163-168
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Kelesidis, Theodoros; Moser, Carlee B; Johnston, Elizabeth et al. (2018) Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s. J Acquir Immune Defic Syndr 78:362-366
Stringer, Elizabeth M; Kendall, Michelle A; Lockman, Shahin et al. (2018) Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy. PLoS One 13:e0199555
Tracy, LaRee A; Struble, Kimberly; Firnhaber, Cynthia et al. (2018) Age Differences by Sex in Antiretroviral-Naïve Participants: Pooled Analysis from Randomized Clinical Trials. J Assoc Nurses AIDS Care 29:371-382
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Lidofsky, Anna; Holmes, Jacinta A; Feeney, Eoin R et al. (2018) Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis 218:1394-1403
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Kelesidis, Theodoros; Kendall, Michelle A; Danoff, Ann et al. (2018) Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332. Medicine (Baltimore) 97:e10955

Showing the most recent 10 out of 165 publications